StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TGTXBearishEarningsnews
High materiality7/10

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

May 5, 2025, 5:01 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Despite strong sales growth, the missed EPS target indicates underlying issues, affecting investor sentiment. Historically, similar misses have caused significant stock price drops.

AI summary

What happened, with direct paths to the underlying reporting

TGTX reported Q1 earnings per share of 3 cents, missing expectations. Sales reached $120.86 million, exceeding consensus of $118.43 million. Briumvi's U.S. net sales were $119.7 million, reflecting strong market adoption. Long-term projections for Briumvi revenue increased to $560 million for 2025. Stock fell 13.2% despite positive sales growth and future forecasts.

  • TGTX reported Q1 earnings per share of 3 cents, missing expectations.
  • Sales reached $120.86 million, exceeding consensus of $118.43 million.
  • Briumvi's U.S. net sales were $119.7 million, reflecting strong market adoption.
  • Long-term projections for Briumvi revenue increased to $560 million for 2025.
  • Stock fell 13.2% despite positive sales growth and future forecasts.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.